Axel Schumacher

Last updated
Axel Schumacher
Born (1969-06-14) June 14, 1969 (age 55)
Kreuztal, Germany
OccupationBiologist
Website Official website OOjs UI icon edit-ltr-progressive.svg

Axel Schumacher (born June 14, 1969), is a German epigenetics researcher. He invented the first microarray technologies for epigenetic biomarker discovery, developed the epigenetic theory of aging with his research leading to the worldwide first proof of whole genome epigenetic abnormalities in Alzheimer's disease.

Contents

Alongside his work as a scientist he is a published author, a futurologist and as of July 2017, CEO and co-founder of the HLTH.network.

Early life and education

Schumacher was born in Kreuztal, Germany in 1969. Schumacher was awarded with a PhD in biology from University of Cologne under the supervision of Robert Koch Prize  [ de ] laureate Walter Doerfler  [ de ] in 2002.

Career

Epigenetics

Schumacher started his career in epigenetics as a visiting researcher at the laboratory of Wolf Reik at the Babraham Institute near Cambridge, England working on DNA methylation and genomic imprinting.

During his career he made several breakthrough discoveries including, how genomic imprinting is regulated by DNA methylation, [1] [2] the effect of in vitro manipulation on imprinted regions in the genome, [3] the first description of ‘epigenetic SNPs’, [4] the invention of single-cell epigenomics, [5] with his research leading to the world's first proof of whole genome epigenetic abnormalities in Alzheimer's disease, [6] indicating that the main predisposing factors for Alzheimer's disease, PSEN and APOE, have a high interindividual variation in humans, which could indicate they are prone to epigenetic abnormalities.

Schumacher invented the technology of ‘epigenetic microarrays’, [7] a technology that transformed the research field and led to hundreds of research discoveries across the world, including the first worldwide proof of whole genome epigenetic changes in schizophrenia and bipolar disorder. [8]

In 2010, Schumacher proposed the ‘epigenetic theory of aging’ a new unifying model of aging and the development of complex diseases, incorporating classical aging theories and epigenetics. [9] His work on epigenetic drift and age-related epigenetic changes in mice and humans [10] [11] laid the foundation to the epigenetic clock theory of aging.

Other work

During the 1990s, Schumacher worked as comic book author and artist. [12] Among others he worked alongside famous artists such as Russian painter Oleg Yudin [13] on titles such as 'High Speed' [14] and on various stories for the American science fiction and fantasy comics magazine Heavy Metal .

Related Research Articles

<span class="mw-page-title-main">Epigenetics</span> Study of DNA modifications that do not change its sequence

In biology, epigenetics is the study of heritable traits, or a stable change of cell function, that happen without changes to the DNA sequence. The Greek prefix epi- in epigenetics implies features that are "on top of" or "in addition to" the traditional genetic mechanism of inheritance. Epigenetics usually involves a change that is not erased by cell division, and affects the regulation of gene expression. Such effects on cellular and physiological phenotypic traits may result from environmental factors, or be part of normal development. Epigenetic factors can also lead to cancer.

<span class="mw-page-title-main">5-Methylcytosine</span> Chemical compound which is a modified DNA base

5-Methylcytosine is a methylated form of the DNA base cytosine (C) that regulates gene transcription and takes several other biological roles. When cytosine is methylated, the DNA maintains the same sequence, but the expression of methylated genes can be altered. 5-Methylcytosine is incorporated in the nucleoside 5-methylcytidine.

<span class="mw-page-title-main">DNA methylation</span> Biological process

DNA methylation is a biological process by which methyl groups are added to the DNA molecule. Methylation can change the activity of a DNA segment without changing the sequence. When located in a gene promoter, DNA methylation typically acts to repress gene transcription. In mammals, DNA methylation is essential for normal development and is associated with a number of key processes including genomic imprinting, X-chromosome inactivation, repression of transposable elements, aging, and carcinogenesis.

<span class="mw-page-title-main">Epigenome</span> Biological term

In biology, the epigenome of an organism is the collection of chemical changes to its DNA and histone proteins that affects when, where, and how the DNA is expressed; these changes can be passed down to an organism's offspring via transgenerational epigenetic inheritance. Changes to the epigenome can result in changes to the structure of chromatin and changes to the function of the genome. The human epigenome, including DNA methylation and histone modification, is maintained through cell division. The epigenome is essential for normal development and cellular differentiation, enabling cells with the same genetic code to perform different functions. The human epigenome is dynamic and can be influenced by environmental factors such as diet, stress, and toxins.

<span class="mw-page-title-main">Methylation specific oligonucleotide microarray</span> Technique used to map epigenetic methylations in cancer DNA

Methylation specific oligonucleotide microarray, also known as MSO microarray, was developed as a technique to map epigenetic methylation changes in DNA of cancer cells.

<span class="mw-page-title-main">Bisulfite sequencing</span> Lab procedure detecting 5-methylcytosines in DNA

Bisulfitesequencing (also known as bisulphite sequencing) is the use of bisulfite treatment of DNA before routine sequencing to determine the pattern of methylation. DNA methylation was the first discovered epigenetic mark, and remains the most studied. In animals it predominantly involves the addition of a methyl group to the carbon-5 position of cytosine residues of the dinucleotide CpG, and is implicated in repression of transcriptional activity.

<span class="mw-page-title-main">DNA (cytosine-5)-methyltransferase 3A</span> Protein-coding gene in the species Homo sapiens

DNA (cytosine-5)-methyltransferase 3A (DNMT3A) is an enzyme that catalyzes the transfer of methyl groups to specific CpG structures in DNA, a process called DNA methylation. The enzyme is encoded in humans by the DNMT3A gene.

<span class="mw-page-title-main">Computational epigenetics</span>

Computational epigenetics uses statistical methods and mathematical modelling in epigenetic research. Due to the recent explosion of epigenome datasets, computational methods play an increasing role in all areas of epigenetic research.

Epigenomics is the study of the complete set of epigenetic modifications on the genetic material of a cell, known as the epigenome. The field is analogous to genomics and proteomics, which are the study of the genome and proteome of a cell. Epigenetic modifications are reversible modifications on a cell's DNA or histones that affect gene expression without altering the DNA sequence. Epigenomic maintenance is a continuous process and plays an important role in stability of eukaryotic genomes by taking part in crucial biological mechanisms like DNA repair. Plant flavones are said to be inhibiting epigenomic marks that cause cancers. Two of the most characterized epigenetic modifications are DNA methylation and histone modification. Epigenetic modifications play an important role in gene expression and regulation, and are involved in numerous cellular processes such as in differentiation/development and tumorigenesis. The study of epigenetics on a global level has been made possible only recently through the adaptation of genomic high-throughput assays.

Methylated DNA immunoprecipitation is a large-scale purification technique in molecular biology that is used to enrich for methylated DNA sequences. It consists of isolating methylated DNA fragments via an antibody raised against 5-methylcytosine (5mC). This technique was first described by Weber M. et al. in 2005 and has helped pave the way for viable methylome-level assessment efforts, as the purified fraction of methylated DNA can be input to high-throughput DNA detection methods such as high-resolution DNA microarrays (MeDIP-chip) or next-generation sequencing (MeDIP-seq). Nonetheless, understanding of the methylome remains rudimentary; its study is complicated by the fact that, like other epigenetic properties, patterns vary from cell-type to cell-type.

The Epigenomics database at the National Center for Biotechnology Information was a database for whole-genome epigenetics data sets. It was retired on 1 June 2016.

<span class="mw-page-title-main">Cancer epigenetics</span> Field of study in cancer research

Cancer epigenetics is the study of epigenetic modifications to the DNA of cancer cells that do not involve a change in the nucleotide sequence, but instead involve a change in the way the genetic code is expressed. Epigenetic mechanisms are necessary to maintain normal sequences of tissue specific gene expression and are crucial for normal development. They may be just as important, if not even more important, than genetic mutations in a cell's transformation to cancer. The disturbance of epigenetic processes in cancers, can lead to a loss of expression of genes that occurs about 10 times more frequently by transcription silencing than by mutations. As Vogelstein et al. points out, in a colorectal cancer there are usually about 3 to 6 driver mutations and 33 to 66 hitchhiker or passenger mutations. However, in colon tumors compared to adjacent normal-appearing colonic mucosa, there are about 600 to 800 heavily methylated CpG islands in the promoters of genes in the tumors while these CpG islands are not methylated in the adjacent mucosa. Manipulation of epigenetic alterations holds great promise for cancer prevention, detection, and therapy. In different types of cancer, a variety of epigenetic mechanisms can be perturbed, such as the silencing of tumor suppressor genes and activation of oncogenes by altered CpG island methylation patterns, histone modifications, and dysregulation of DNA binding proteins. There are several medications which have epigenetic impact, that are now used in a number of these diseases.

An epigenetic clock is a biochemical test that can be used to measure age. The test is based on modifications that change over time and regulate how genes are expressed. Typically, the test examines DNA methylation levels, measuring the accumulation of methyl groups to one's DNA molecules, or more recently, based on the histone code.

<span class="mw-page-title-main">Epigenome editing</span>

Epigenome editing or epigenome engineering is a type of genetic engineering in which the epigenome is modified at specific sites using engineered molecules targeted to those sites. Whereas gene editing involves changing the actual DNA sequence itself, epigenetic editing involves modifying and presenting DNA sequences to proteins and other DNA binding factors that influence DNA function. By "editing” epigenomic features in this manner, researchers can determine the exact biological role of an epigenetic modification at the site in question.

<span class="mw-page-title-main">Whole genome bisulfite sequencing</span>

Whole genome bisulfite sequencing is a next-generation sequencing technology used to determine the DNA methylation status of single cytosines by treating the DNA with sodium bisulfite before high-throughput DNA sequencing. The DNA methylation status at various genes can reveal information regarding gene regulation and transcriptional activities. This technique was developed in 2009 along with reduced representation bisulfite sequencing after bisulfite sequencing became the gold standard for DNA methylation analysis.

H3K27me3 is an epigenetic modification to the DNA packaging protein histone H3. It is a mark that indicates the tri-methylation of lysine 27 on histone H3 protein.

<span class="mw-page-title-main">Epigenome-wide association study</span>

An epigenome-wide association study (EWAS) is an examination of a genome-wide set of quantifiable epigenetic marks, such as DNA methylation, in different individuals to derive associations between epigenetic variation and a particular identifiable phenotype/trait. When patterns change such as DNA methylation at specific loci, discriminating the phenotypically affected cases from control individuals, this is considered an indication that epigenetic perturbation has taken place that is associated, causally or consequentially, with the phenotype.

Susan J. Clark is an Australian biomedical researcher in epigenetics of development and cancer. She was elected a Fellow of the Australian Academy of Science in 2015, and is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow and Research Director and Head of Genomics and Epigenetics Division at the Garvan Institute of Medical Research. Clark developed the first method for bisulphite sequencing for DNA methylation analysis and used it to establish that the methylation machinery of mammalian cells is capable of both maintenance and de novo methylation at CpNpG sites and showed is inheritable. Clark's research has advanced understanding of the role of DNA methylation, non-coding RNA and microRNA in embryogenesis, reprogramming, stem cell development and cancer, and has led to the identification of epigenomic biomarkers in cancer. Clark is a founding member of the International Human Epigenome Consortium (IHEC) and President of the Australian Epigenetics Alliance (AEpiA).

H4K20me is an epigenetic modification to the DNA packaging protein Histone H4. It is a mark that indicates the methylation at the 20th lysine residue of the histone H4 protein. This mark can be mono-, di-, or tri-methylated. It is critical for genome integrity including DNA damage repair, DNA replication and chromatin compaction.

<span class="mw-page-title-main">Epiphenotyping</span> Epiphenotyping is the use of DNA methylation patterns to predict phenotypes.

Epiphenotyping involves studying the relationship between DNA methylation patterns and phenotypic traits in individuals and populations to be able to predict a phenotype from a DNA methylation profile. In the following sections, the background of epiphenotyping, an overview of a general methodology, its applications, advantages, and limitations are covered.

References

  1. Schumacher, Axel; Buiting, Karin; Zeschnigk, Michael; Doerfler, Walter; Horsthemke, Bernhard (August 1998). "Methylation analysis of the PWS/AS region does not support an enhancer-competition model". Nature Genetics. 19 (4): 324–325. doi: 10.1038/1211 . ISSN   1546-1718. PMID   9697691. S2CID   28353445.
  2. Schumacher, A.; Koetsier, P. A.; Hertz, J.; Doerfler, W. (2000-12-01). "Epigenetic and genotype-specific effects on the stability of de novo imposed methylation patterns in transgenic mice". The Journal of Biological Chemistry. 275 (48): 37915–37921. doi: 10.1074/jbc.M004839200 . ISSN   0021-9258. PMID   10954710.
  3. Schumacher, Axel; Doerfler, Walter (2004). "Influence of in vitro manipulation on the stability of methylation patterns in the Snurf/Snrpn-imprinting region in mouse embryonic stem cells". Nucleic Acids Research. 32 (4): 1566–1576. doi:10.1093/nar/gkh322. ISSN   1362-4962. PMC   390307 . PMID   15004243.
  4. Schumacher, Axel; Friedrich, Patricia; Diehl-Schmid, Janine; Ibach, Bernd; Eisele, Tamara; Laws, Simon M.; Förstl, Hans; Kurz, Alexander; Riemenschneider, Matthias (November 2007). "No association of chromatin-modifying protein 2B with sporadic frontotemporal dementia". Neurobiology of Aging. 28 (11): 1789–1790. doi:10.1016/j.neurobiolaging.2006.07.016. ISSN   1558-1497. PMID   16979267. S2CID   30744877.
  5. Kantlehner, Martin; Kirchner, Roland; Hartmann, Petra; Ellwart, Joachim W.; Alunni-Fabbroni, Marianna; Schumacher, Axel (April 2011). "A high-throughput DNA methylation analysis of a single cell". Nucleic Acids Research. 39 (7): e44. doi:10.1093/nar/gkq1357. ISSN   0305-1048. PMC   3074158 . PMID   21266484.
  6. Wang, Sun-Chong; Oelze, Beatrice; Schumacher, Axel (2008-07-16). "Age-specific epigenetic drift in late-onset Alzheimer's disease". PLOS ONE. 3 (7): e2698. Bibcode:2008PLoSO...3.2698W. doi: 10.1371/journal.pone.0002698 . ISSN   1932-6203. PMC   2444024 . PMID   18628954.
  7. Schumacher, Axel; Kapranov, Philipp; Kaminsky, Zachary; Flanagan, James; Assadzadeh, Abbas; Yau, Patrick; Virtanen, Carl; Winegarden, Neil; Cheng, Jill; Gingeras, Thomas; Petronis, Arturas (2006). "Microarray-based DNA methylation profiling: technology and applications". Nucleic Acids Research. 34 (2): 528–542. doi:10.1093/nar/gkj461. ISSN   1362-4962. PMC   1345696 . PMID   16428248.
  8. Mill, Jonathan; Tang, Thomas; Kaminsky, Zachary; Khare, Tarang; Yazdanpanah, Simin; Bouchard, Luigi; Jia, Peixin; Assadzadeh, Abbas; Flanagan, James; Schumacher, Axel; Wang, Sun-Chong (March 2008). "Epigenomic profiling reveals DNA-methylation changes associated with major psychosis". American Journal of Human Genetics. 82 (3): 696–711. doi:10.1016/j.ajhg.2008.01.008. ISSN   1537-6605. PMC   2427301 . PMID   18319075.
  9. Schumacher, Axel (2010). Handbook of Epigenetics: The New Molecular and Medical Genetics. Academic. pp. 405–422. ISBN   978-0123757098.
  10. Schumacher, Axel (Jan 2009). "An epigenetic clock: Anticorrelation & DNA methylation as biomarker for aging". ResearchGate.
  11. Wang, Sun-Chong; Oelze, Beatrice; Schumacher, Axel (2008-07-16). "Age-specific epigenetic drift in late-onset Alzheimer's disease". PLOS ONE. 3 (7): e2698. Bibcode:2008PLoSO...3.2698W. doi: 10.1371/journal.pone.0002698 . ISSN   1932-6203. PMC   2444024 . PMID   18628954.
  12. "Axel Schumacher". lambiek.net. Retrieved 2021-08-17.
  13. "High Speed (2000) issue OGN SC vol. 01". comicbookcollect.com. Retrieved 2021-08-17.
  14. "Oleg Yudin". lambiek.net. Retrieved 2021-08-17.